nivolumab (subcutaneous)

Nivolumab (subcutaneous) is an investigational formulation of the programmed death-1 (PD-1) immune checkpoint inhibitor nivolumab, developed by Bristol Myers Squibb. This formulation is designed for subcutaneous (SC) administration, typically utilizing recombinant human hyaluronidase (rHuPH20) to facilitate the delivery of large volumes into the subcutaneous space. Nivolumab is a human IgG4 monoclonal antibody that binds to the PD-1 receptor on T-cells, inhibiting its interaction with the ligands PD-L1 and PD-L2. By blocking this pathway, nivolumab restores the ability of T-cells to recognize and attack tumor cells. In clinical development for non-small cell lung cancer (NSCLC), the subcutaneous formulation is being evaluated to provide a more convenient and faster administration option compared to the standard intravenous infusion, potentially improving the patient experience and healthcare efficiency.

Brand names

Opdivo

Other names

nivolumab SCsubcutaneous nivolumabOpdivo SC